Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | BMC Neuroscience

Fig. 5

From: Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies

Fig. 5

Analysis of astrogliosis in 3R Tau transgenic mice treated with CBL a Immunocytochemistry with an antibody against GFAP in the 3–6 month group. b Computer aided image analysis of levels of GFAP immunoreactivity in the neocortex and hippocampus in the 3–6 month group. c Immunocytochemistry with an antibody against GFAP in the brains of the 6–9 month group. d Computer aided image analysis of levels of GFAP immunoreactivity in the neocortex and hippocampus in the 6–9 month group. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. *P < 0.05 when compared to non-tg control using one way ANOVA with Dunnet’s post hoc test. # P < 0.05 when compared to vehicle-treated tg mice control using one way ANOVA with Dunnet’s post hoc test

Back to article page